DOACs: Perioperative Management

Thrombosis Canada
Thrombose Canada

Objectives:

To provide guidance for the perioperative management of patients who are receiving a newer direct oral anticoagulant (DOAC) and require an elective surgery/procedure.

For guidance on management of patients who require an urgent or emergency surgery/procedure, please refer to the Perioperative Anticoagulant Management Algorithm found on the Thrombosis Canada website under the "Tools" tab.

Background:

Four DOACs (apixaban, dabigatran, edoxaban and rivaroxaban) are approved for clinical use in Canada based on findings from large randomized trials.

The perioperative management of DOAC-treated patients aims to minimize thromboembolic risk while interrupting anticoagulant therapy (if necessary) so there is no (or minimal) residual anticoagulant effect at the time of surgery, and to ensure timely but careful resumption after surgery so as to not incur an increased risk for post-operative bleeding.

There are 3 important considerations for perioperative management of patients taking a DOAC:

1. Reliable laboratory tests are not widely available to confirm a pre-operative minimal or no residual anticoagulant effect of DOACs.
2. Half-lives of DOACs are, overall, 10-12 hours, thereby informing when the drug should be stopped before surgery. In the case of dabigatran, which is cleared mainly by the kidney, the half-life can be longer (18-24 hours) in patients with impaired renal function.
3. DOACs have a rapid onset of action, with a peak anticoagulant effect occurring 1-2 hours after oral intake, thereby requiring caution with postoperative resumption.

In the absence of laboratory tests to reliably measure their anticoagulant effect, the perioperative administration of DOACs should be influenced by:

- Drug elimination half-life (with normal renal function),
- Effect of renal function on drug elimination half-life
- Bleeding risk associated with the type of surgery/procedure and anesthesia (specifically neuraxial blockade) (**Table 1**)

Importantly, the bleed risk stratification outlined in **Table 1** is empiric in nature. Bleed risk stratification should account for patient-specific factors (e.g., concurrent antiplatelet therapy, prior history of major bleeding), as well as procedure-specific factors (proceduralist preferences, anticipated invasiveness of the procedure in question). The proposed bleed risk classifications are suggestions only. Factors that might otherwise increase or decrease the perceived bleeding risk should also be considered.

Table 1. Bleeding Risk for Various Invasive/Surgical Procedures

LOW/VERY LOW RISK	MODERATE RISK	HIGH RISK
• Cataract surgery • Dermatologic procedures (e.g. biopsy) • Gastroscopy or colonoscopy without biopsies • Coronary angiography (using radial arterial approach) • Permanent pacemaker insertion or internal defibrillator placement (if bridging anticoagulation is not used) • Selected procedures with small-bore needles (e.g. thoracentesis, paracentesis, arthrocentesis) • Dental extractions (1 or 2 teeth) • Endodontic (root canal) procedure • Subgingival scaling or other cleaning	• Abdominal surgery (e.g. cholecystectomy, hernia repair) • Other general surgery (e.g. breast) • Other intrathoracic surgery • Other orthopedic surgery • Other vascular surgery • Non-cataract ophthalmologic surgery • Coronary angiography (using femoral artery approach) • Gastroscopy or colonoscopy with biopsies • Selected procedures with large-bore needles (e.g. bone marrow biopsy, lymph node biopsy) • Complex dental procedure (e.g. multiple tooth extractions)	• Any surgery or procedure with neuraxial (spinal or epidural) anesthesia • Neurosurgery (intracranial or spinal) • Cardiac surgery (e.g. CABG, heart valve replacement) • Major vascular surgery (e.g. aortic aneurysm repair, aortofemoral bypass) • Major orthopedic surgery (e.g. hip/knee joint replacement surgery) • Lung resection surgery • Urological surgery (e.g. prostatectomy, bladder tumour resection) • Extensive cancer surgery (e.g. pancreas, liver) • Intestinal anastomosis surgery • Reconstructive plastic surgery • Selected procedures involving vascular organs (e.g. kidney biopsy, prostate biopsy) or high bleed risk intervention (e.g. pericardiocentesis, spinal injection, polypectomy)

Evidence Supporting Perioperative Management of Patients Taking a DOAC:

There are emerging data relating to the efficacy and safety of the proposed perioperative management of DOAC-treated patients. The PAUSE study assessed a standardized perioperative management strategy in patients who were receiving a DOAC and required DOAC interruption prior to an elective (planned) surgery/procedure. In this study of 3,007 DOAC-treated patients with atrial fibrillation, a simple perioperative DOAC management that did not involve perioperative heparin bridging or preoperative coagulation function testing was associated with low rates of major bleeding (<2%) and stroke/systemic embolism (<1%).

Perioperative Management (based on PAUSE protocol):

Patients Receiving Dabigatran

Perioperative Management (Table 2):

- **MINIMAL-BLEED-RISK procedure:** In patients who require a minor dental procedure, cataract procedure (typically with topical anesthetic), or minor skin procedure it is likely safe not to interrupt DOAC therapy (as is done in warfarin-treated patients) but data to support such practice is lacking. An alternative approach would be to hold dabigatran on the day of the procedure or, if dabigatran is not

interrupted, to delay that day's dose for 4-6 hours after the procedure.
Management should consider patient and procedure-related factors. If dabigatran is not interrupted, we suggest delaying the AM dose 2-3 hours post-procedure and giving the PM dose at the usual time. Alternatively, dabigatran can be omitted on the day of the procedure, especially in circumstances of higher post-procedure bleeding risk.

- **LOW/MODERATE-BLEED-RISK surgery/procedures:** For patients with normal renal function or mild impairment (ClCR $\geq$ 50 mL/min), last dose of dabigatran 2 days before the surgery/procedure (i.e. skip 2 doses before a surgery/procedure), which corresponds to approximately 3 half-lives elapsed between stopping dabigatran and surgery. There may be a 10-15% anticoagulant effect at the time of surgery, which is acceptable for these procedures.
- **HIGH-BLEED-RISK (includes any neuraxial [i.e. spinal or epidural] anesthesia or procedure)**: Depending on renal function, last dose of dabigatran 3 to 5 days before surgery/procedure (i.e. skip 4 to 8 doses), which corresponds to approximately 4-5 half-lives elapsed between stopping dabigatran and surgery. This ensures minimal (3-6%) residual anticoagulant effect at the time of surgery and allows patients to have spinal anesthesia or high bleeding risk surgery (e.g. intracranial or cardiac).
- If renal function is moderately impaired (CrCl 30-49 mL/min), 1-2 additional days of interruption is required for patients on dabigtran to ensure elimination of any residual anticoagulant effect, as 80% of dabigatran is cleared by the kidneys.

Post-Operative Management (Table 3):

Resumption of dabigatran 150 mg or 110 mg twice daily should be done cautiously after major surgery or in patients at increased bleeding risk, as this is a therapeutic dose which is higher than what is used for routine post-operative VTE prophylaxis.

Patients Receiving Rivaroxaban

Perioperative Management (Table 2):

- **MINIMAL-BLEED-RISK procedure**: In patients who require a minor dental procedure, cataract procedure, or minor skin procedure it is likely safe not to interrupt anticoagulation (as is done in warfarin-treated patients) but data to support such practice is lacking. An alternative approach would be to hold rivaroxaban on the day of the procedure or, if rivaroxaban is not interrupted, to delay that day's dose for 4-6 hours after the procedure.
Management should consider patient and procedure-related factors. If rivaroxaban is not interrupted, we suggest delaying the dose until supper time (unless usually taken at this time). Alternatively, rivaroxaban can be omitted on the day of the procedure, especially in circumstances of higher post-procedure bleeding risk
- **LOW/MODERATE-BLEED-RISK surgery/procedure:** Last dose of rivaroxaban 2 days before surgery/procedure (i.e. skip 1 dose), which corresponds to approximately 2-3 half-lives elapsed between stopping rivaroxaban and surgery.
- **HIGH-BLEED-RISK surgery/procedure (includes any neuraxial [i.e., spinal or epidural] anesthesia or procedure)**: Last dose of rivaroxaban 3 days before surgery/procedure (i.e. skip 2 doses), which corresponds to approximately 4-5 half-lives elapsed between stopping rivaroxaban and surgery.

Post-Operative Management (Table 3):

Resumption of rivaroxaban 20 mg (or 15 mg if usual dose) once daily should be done cautiously after major surgery or in patients at increased bleeding risk, as this is a therapeutic dose which is higher than what is used for routine post-operative VTE prophylaxis.

Patients Receiving Apixaban

Perioperative Management (Table 2):

- **MINIMAL-BLEED-RISK procedure:** In patients who require a minor dental procedure, cataract procedure, or minor skin procedure it is likely safe not to interrupt anticoagulation (as is done in warfarin-treated patients) but data to support such practice is lacking. An alternative approach would be to hold apixaban on the day of the procedure or, if apixaban is not interrupted, to delay that day's dose for 4-6 hours after the procedure.
  Management should consider patient and procedure-related factors. If apixaban is not interrupted, we suggest delaying the AM dose 2-3 hours post-procedure and giving the PM dose at the usual time. Alternatively, apixaban can be omitted on the day of the procedure, especially in circumstances of higher post-procedure bleeding risk.
- **LOW/MODERATE-BLEED-RISK surgery/procedure**: Last dose of apixaban 2 days before surgery/procedure (i.e. skip 2 doses), which corresponds to approximately 3 half-lives elapsed between stopping apixaban and surgery.
- **HIGH-BLEED-RISK surgery/procedure (includes any neuraxial [i.e., spinal or epidural] anesthesia or procedure)**: Last dose of apixaban 3 days before surgery/procedure (i.e. skip 4 doses), which corresponds to approximately 4-5 half-lives elapsed between stopping apixaban and surgery.

Post-Operative Management (Table 3):

Resumption of apixaban 5 mg twice daily should be done cautiously after major surgery or in patients at increased bleeding risk, as this is a therapeutic-dose which is higher than what is for routine post-operative VTE prophylaxis.

Patients Receiving Edoxaban

Perioperative Management (Table 2):

- **MINIMAL-BLEED-RISK procedure:** In patients who require a minor dental procedure, cataract procedure, or minor skin procedure it is likely safe not to interrupt anticoagulation (as is done in warfarin-treated patients) but data to support such practice is lacking. An alternative approach would be to hold edoxaban on the day of the procedure or, if edoxaban is not interrupted, to delay that day's dose for 4-6 hours after the procedure.
  Management should consider patient and procedure-related factors. If edoxaban is not interrupted, we suggest delaying the dose until the evening. Alternatively, edoxaban can be omitted on the day of the procedure, especially in circumstances of higher post-procedure bleeding risk.
- **LOW/MODERATE-BLEED-RISK surgery/procedure:** Last dose of edoxaban 2 days before surgery/procedure (i.e. skip 1 dose), which corresponds to approximately 3 half-lives elapsed between stopping edoxaban and surgery.
- **HIGH-BLEED-RISK surgery/procedure (includes any neuraxial [i.e., spinal or epidural] anesthesia or procedure)**: Last dose of edoxaban 3 days before surgery/procedure (i.e. skip 2 doses), which corresponds to approximately 4-5 half-lives elapsed between stopping edoxaban and surgery.

Post-Operative Management (Table 3):


Resumption of edoxaban 60 mg or 30 mg daily should be done cautiously after major surgery or in patients at increased bleeding risk, as this is a therapeutic-dose which is higher than what is used for routine post-operative VTE prophylaxis.

Table 2. Suggested Guide for Pre-Operative Management of Patients Receiving a DOAC

Drug (dose regimen)	Renal function	Moderate Bleed Risk Surgery* *12-25% residual anticoagulant effect at time of surgery acceptable/Procedure*	Major surgery/procedure including neuraxial procedures*† (high bleeding risk) <10% residual anticoagulant effect at time of surgery acceptable
Dabigatran (twice daily)	Normal renal function or mild impairment (CrCl ≥50 mL/min) $t_{1/2}$ 7-17 hours	Give last dose 2 days before surgery/ procedure (i.e. skip 2 doses)	Give last dose 3 days before surgery/procedure (i.e. skip 4 doses)
	Moderate renal impairment (CrCl 30-49 mL/min) $t_{1/2}$ 17-20 hours	Give last dose 3 days before surgery/ procedure (i.e. skip 4 doses)	Give last dose 5 days before surgery/procedure (i.e. skip 8 doses)
Rivaroxaban (once daily)	Normal renal function, mild or moderate impairment (CrCl ≥30 mL/min) $t_{1/2}$ 7-11 hours	Give last dose 2 days before surgery/procedure (i.e. skip 1 dose)	Give last dose 3 days before surgery/procedure (i.e. skip 2 doses)
Apixaban (twice daily)	Normal renal function, mild or moderate impairment (CrCl ≥30 mL/min) $t_{1/2}$ 8-12 hours	Give last dose 2 days before surgery/procedure (i.e. skip 2 doses)	Give last dose 3 days before surgery/procedure (i.e. skip 4 doses)
Edoxaban (once daily)	Normal renal function or mild impairment (CrCl ≥30 mL/min) $t_{1/2}$ 10-14 hours	Give last dose 2 days before surgery/procedure (i.e. skip 1 dose)	Give last dose 3 days before surgery/procedure (i.e. skip 2 doses)

*No anticoagulant taken on the day of surgery/procedure.
†Neuraxial procedures include spinal anesthesia, epidural catheter insertion and epidural catheter removal.

Table 3: Perioperative management of DOACs



†Resumed ~24 hrs after low/moderate-bleed-risk surgery/procedure, and 48-72 hours after high-bleed-risk surgery/procedure.

†In patients considered at high risk for venous thromboembolism, low-dose LMWH (i.e., dalteparin, 5000 IU daily or enoxaparin, 40 mg daily or tinzaparin, 4500 IU daily) can be administered during the initial 48–72-hour post-operative period.

Table 4. Suggested Guide for ***Post-Operative*** Management of Patients Receiving a DOAC

Drug	Moderate Bleeding Risk Surgery/Procedure (Moderate Bleeding Risk)	Major Surgery/Procedure (High Bleeding Risk)
Dabigatran	Resume on day after surgery (~24 hours post-operative)	Resume therapeutic doses 2-3 days after surgery (~48-72 hours post-operative); prophylactic dose anticoagulants can be considered in the interim
Rivaroxaban	Resume on day after surgery (~24 hours post-operative)	Resume therapeutic doses 2-3 days after surgery (~48-72 hours post-operative); prophylactic dose anticoagulants can be considered in the interim
Apixaban	Resume on day after surgery (~24 hours post-operative)	Resume therapeutic doses 2-3 days after surgery (~48-72 hours post-operative); prophylactic dose anticoagulants can be considered in the interim
Edoxaban	Resume on day after surgery (~24 hours post-operative)	Resume therapeutic doses 2-3 days after surgery (~48-72 hours post-operative); prophylactic dose anticoagulants can be considered in the interim

Special Considerations:

Patients with Impaired Renal Function:

An approach to managing patients with mild-to-moderate renal dysfunction is shown in **Table 2,** but for patients with severe renal dysfunction (CrCl <30 mL/min) who are generally ineligible for DOACs, perioperative management is unclear. Some guidance (e.g., Doherty et al 2017) recommend interrupting factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) for an additional 12-24 hours (depending on procedural bleed risk) in patients with severe renal dysfunction (CrCl < 30 mL/min), like the strategy outlined above for dabigatran. Caution is warranted with this approach since it is based on little data. Results from a small single center retrospective cohort study (Hrubesz et al. 2024) of apixaban-treated patients with advanced chronic kidney disease (CrCl < 30 mL/min) undergoing elective surgery found that clinicians tended to hold apixaban for 1-2 days longer than would be expected with standard PAUSE management. With this approach, the risk of major bleeding attributable to surgery appeared similar to that observed in the PAUSE study.

Need for Bridging in DOAC-treated Patients:

In general, the rapid offset and onset of action of DOACs obviates the need for 'heparin bridging' as is done in selected warfarin-treated patients.

Other Relevant Thrombosis Canada Clinical Guides:

- Apixaban (Eliquis®)
- Dabigatran (Pradaxa®)

- DOACs: Coagulation Tests
- DOACs: Comparison and Frequently Asked Questions
- Edoxaban (Lixiana®)
- Rivaroxaban (Xarelto®)

Help sustain trusted thrombosis guidance.

Ongoing expert review and regular updates ensure Thrombosis Canada's clinical guides remain current and reliable. Your support helps protect the quality and continuity of these resources for clinicians nationwide. https://thrombosiscanada.ca/hcp/Donate-2

References:

Doherty JU, et al. 2017 ACC Expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: A report of the american college of cardiology clinical expert consensus document task force. J Am Coll Cardiol 2017;69(7):871-898.

Douketis JD, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019;179(11):1469-1478.

Douketis JD, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest 2022;162(5):E207-E243.

Douketis J, Spyropoulos A. Perioperative management of anticoagulant and antiplatelet therapy. NEJM Evid 2023;2(6).

Hrubesz G, et al. Perioperative management of apixaban in patients with advanced CKD undergoing a planned invasive procedure. Blood Adv. 2024;8(3):732-735.

Macle L, et al. for the CCS Atrial Fibrillation Guidelines Committee. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2016;32:1170-1185.

Monagle P, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e737S-801S.

Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012;119(13):3016-3023.

Shaw JR, et al. Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2018:2:282-290.

Shaw JR, et al. Periprocedural Management of Oral Anticoagulation. Med Clin North Am 2020;104(4): 709-726.

Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost. 2016;14:875-85.

Date of Version: 29May2025

Please note that the information contained herein is not to be interpreted as an alternative to medical advice from your doctor or other professional healthcare provider. If you have any specific questions about any medical matter, you should consult your doctor or other professional healthcare providers, and as such you should never delay seeking medical advice, disregard medical advice or discontinue medical treatment because of the information contained herein.